Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +0.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,179)

clinicaltrialsPublishedShowing 401–450 of 3,550 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04933695	A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment(CodeBreaK201)	terminated	Phase 2	42	AmgenINDUSTRY	10	Jul 13, 2026	clinicaltrials
NCT05451849	A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	terminated	Phase 1 / Phase 2	14	TCR2 TherapeuticsINDUSTRY	1	Jul 13, 2026	clinicaltrials